Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemoradiotherapy in Stage IV Head and Neck Squamous Cell Carcinoma
NCT02819752Phase 1Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2017
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Number and Percentage of Patients With Dose Limiting Toxicities and Acute Toxicity as Measured During Treatment by CTCAE v4.0. Started Jul 2017; status: terminated.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02819752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819752.